-
-
-
-
-
-
-
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
-
-
-
-
-
-
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
-
-
-
-
-
-
-
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

